Goldman Sachs
LGND icon

Goldman Sachs’s Ligand Pharmaceuticals LGND Stock Holding History

Goldman Sachs’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-54,502
Closed -$5.18M – 6380
2021
Q1 		$5.18M Sell
54,502
-201,177
-79% -$19M ﹤0.01% 3105
2020
Q4 		$15.9M Sell
255,679
-213,038
-45% -$12.1M ﹤0.01% 2046
2020
Q3 		$27.9M Buy
468,717
+42,640
+10% +$2.91M 0.01% 1475
2020
Q2 		$29.7M Buy
426,077
+298,799
+235% +$18.9M 0.01% 1365
2020
Q1 		$5.77M Sell
127,278
-370,133
-74% -$21M ﹤0.01% 2527
2019
Q4 		$32.4M Buy
497,411
+76,143
+18% +$5.09M 0.01% 1475
2019
Q3 		$26.2M Buy
421,268
+228,908
+119% +$14.4M 0.01% 1584
2019
Q2 		$13.7M Sell
192,360
-1,924
-1% -$142K ﹤0.01% 2136
2019
Q1 		$15.2M Buy
194,284
+173,926
+854% +$13.2M ﹤0.01% 2098
2018
Q4 		$1.72M Buy
+20,358
New +$2.17M ﹤0.01% 3615
2017
Q1 		– Sell
-17,793
Closed -$1.13M – 6898
2016
Q4 		$1.13M Buy
17,793
+6,572
+59% +$415K ﹤0.01% 4343
2016
Q3 		$714K Buy
+11,221
New +$824K ﹤0.01% 4714
2014
Q4 		– Sell
-72,135
Closed -$2.12M – 7221
2014
Q3 		$2.12M Buy
72,135
+32,060
+80% +$1.06M ﹤0.01% 3882
2014
Q2 		$1.56M Buy
+40,075
New +$1.63M ﹤0.01% 4249
2013
Q3 		– Sell
-80,150
Closed -$1.87M – 6633
2013
Q2 		$1.87M Buy
+80,150
New +$1.44M ﹤0.01% 3794

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Goldman Sachs's LGND Position: Q1 2026 in Review

Goldman Sachs reduced its Ligand Pharmaceuticals (LGND) stake by 11% in Q1 2026, selling an estimated $9.48M and leaving 381,111 shares worth $76.1M. The position accounts for 0.01% of the portfolio, ranked #1237.

Goldman Sachs first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $81.1M in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Goldman Sachs held 381,111 shares of Ligand Pharmaceuticals worth $76.1M as of Q1 2026.
  • Goldman Sachs sold 47,893 Ligand Pharmaceuticals shares in Q1 2026, an estimated $9.48M.
  • Ligand Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1237 holding.
  • Goldman Sachs first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Ligand Pharmaceuticals position peaked at $81.1M in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.